Physicians' Academy for Cardiovascular Education

PCSK9 inhibitor changes levels and sizes of lipoprotein particles

Effect of Evolocumab on Lipoprotein Particles

Literature - Toth PP, Sattar N, Blom DJ, et al. - Am J Cardiol 2018;121:308–314

Main results

Conclusion

Evolocumab significantly changes lipoprotein particle number and size. Treatment with the PCSK9 inhibitor was associated with lower concentrations of total LDL-c, small LDL-p and large LDL-p. These findings may help guide therapeutic decisions in patients with hyperlipidemia.

References

Show references

Download the slide Find this article online at Am J Cardiol 2018

Click to view the slide

Share this page with your colleagues and friends: